The FDA has signed off on a Phase 1a/b proof-of-concept study evaluating Aligos Therapeutics' (ALGS) ALG-000184 for the potential treatment (functional cure) of hepatitis B virus (HBV) infection.
ALG-000184 is a small molecule class II capsid assembly modulator (CAM) that works by targeting the HBV capsid assembly and the establishment covalently closed circular DNA (DNA structure that arises from the propagation of the virus).
The company just filed a preliminary prospectus for an IPO.
https://seekingalpha.com/news/3617696-fda-on-board-early-stage-study-of-aligos-hbv-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.